Steve Elms - Jun 10, 2021 Form 4 Insider Report for Zosano Pharma Corp (ZSAN)

Role
Director
Signature
/s/ Steven Lo, Attorney-in-Fact for Steve Elms
Stock symbol
ZSAN
Transactions as of
Jun 10, 2021
Transactions value $
$0
Form type
4
Date filed
6/14/2021, 08:38 PM
Previous filing
Jun 10, 2021
Next filing
Mar 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZSAN Common Stock Award $0 +15K +200% $0.00 22.5K Jun 10, 2021 Direct F1
holding ZSAN Common Stock 2.72M Jun 10, 2021 (2) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZSAN Stock Option (Right to Buy) Award $0 +30K $0.00 30K Jun 10, 2021 Common Stock 30K $0.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units which vest in a single installment on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date.
F2 Represents shares directly held by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3 The option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date.